Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ene.12883 http://scihub22266oqcxt.onion/10.1111/ene.12883 C4670697!4670697!26563094     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26563094&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Neurol 2016 ; 23 (Suppl 1): 18-27 Nephropedia Template TP {{tp|p=26563094|t=2016. Disease-modifying treatments for multiple sclerosis ? a review of approved medications |pdf=|usr=}}{{26563094}} gab.com Text Disease-modifying treatments for multiple sclerosis a review of approved medications JO: Eur J Neurol http://www.kidney.de/pget.php?&tw=1&pmid=26563094 #FOAvip Background and purpose: There is still no curative treatment for multiple sclerosis (MS), but during the last 20 years eight different disease-modifying compounds have been approved for relapsing?remitting MS (RRMS). Methods: A literature search was conducted on published randomized controlled phase III trials indexed in PubMed on the approved medications until 21 May 2015. Results: In this review the mode of action, documented treatment effects and side effects of the approved MS therapies are briefly discussed. Conclusions: Based on current knowledge of risk?benefit of the approved MS medications, including factors influencing adherence, it is suggested that oral treatment with dimethyl fumarate or teriflunomide should be preferred as a starting therapy amongst the first-line preparations for de novo RRMS. In the case of breakthrough disease on first-line therapy, or rapidly evolving severe RRMS, second-line therapy with natalizumab, fingolimod or alemtuzumab should be chosen based on careful risk?benefit stratification. Twit Text FOAVip Disease-modifying treatments for multiple sclerosis a review of approved medications ????Eur J Neurol http://www.kidney.de/pget.php?&tw=1&pmid=26563094 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26563094 #FOAvip English Wikipedia <ref>{{Cite pmid|26563094}}</ref> Disease-modifying treatments for multiple sclerosis ? a review of approved medications #MMPMID26563094 Torkildsen Ø; Myhr KM; Bø L Eur J Neurol 2016[Jan]; 23 (Suppl 1): 18-27 PMID26563094show ga Background and purpose: There is still no curative treatment for multiple sclerosis (MS), but during the last 20 years eight different disease-modifying compounds have been approved for relapsing?remitting MS (RRMS). Methods: A literature search was conducted on published randomized controlled phase III trials indexed in PubMed on the approved medications until 21 May 2015. Results: In this review the mode of action, documented treatment effects and side effects of the approved MS therapies are briefly discussed. Conclusions: Based on current knowledge of risk?benefit of the approved MS medications, including factors influencing adherence, it is suggested that oral treatment with dimethyl fumarate or teriflunomide should be preferred as a starting therapy amongst the first-line preparations for de novo RRMS. In the case of breakthrough disease on first-line therapy, or rapidly evolving severe RRMS, second-line therapy with natalizumab, fingolimod or alemtuzumab should be chosen based on careful risk?benefit stratification. äDisease-modifying treatments for multiple sclerosis ? a review of appr(epmc).pdf DeepDyve Pubget Overpricing